Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $42.33

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $42.33.

KROS has been the subject of a number of research analyst reports. William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th. Scotiabank decreased their target price on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research report on Thursday, January 16th. Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th. BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $15.00 price objective on shares of Keros Therapeutics in a research report on Tuesday.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $9.55 on Friday. The firm has a 50-day moving average of $11.10 and a 200-day moving average of $33.64. Keros Therapeutics has a one year low of $9.41 and a one year high of $72.37. The company has a market cap of $387.37 million, a P/E ratio of -1.83 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. As a group, research analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently modified their holdings of KROS. AlphaQuest LLC raised its holdings in Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after acquiring an additional 2,964 shares during the period. Virtus ETF Advisers LLC grew its position in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock valued at $61,000 after purchasing an additional 1,998 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Keros Therapeutics during the 4th quarter valued at $90,000. Exchange Traded Concepts LLC purchased a new stake in Keros Therapeutics during the 4th quarter worth about $99,000. Finally, CANADA LIFE ASSURANCE Co boosted its stake in Keros Therapeutics by 207.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company’s stock worth $116,000 after purchasing an additional 4,976 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.